Perivascular epithelioid cell tumour (PEComa)
Prepared with OnCo (onco.cc/prep/pecoma/). Orientation, not medical advice; your team knows your case.
My details
What I know, what is unclear, changes to discuss
Saved in this browserMy questions
16 on the sheet- 1.What is my exact diagnosis, stage, and grade, and which tests established them?
- 2.Which biomarkers have been tested on my tumour (for example TSC1 or TSC2 inactivation, TFE3 fusion, HMB-45, Melan-A and smooth muscle actin co-expression, Size over 5 cm, mitoses, necrosis and infiltration), and what were the results?
- 3.Which subtype is my cancer, and does that change the recommended treatment?
- 4.Is germline (inherited) genetic testing recommended for me or my family?
- 5.For my situation (localised), which of the standard options do you recommend and why?
- 6.For my situation (advanced malignant pecoma), which of the standard options do you recommend and why?
- 7.Am I a candidate for Sirolimus protein-bound particles, Everolimus, Temsirolimus, and what side effects should I expect?
- 8.How do the results of AMPECT apply to someone like me?
- 9.For my situation (after mtor inhibitor), which of the standard options do you recommend and why?
- 10.Am I a candidate for Doxorubicin, Gemcitabine, and what side effects should I expect?
- 11.How do the results of Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) apply to someone like me?
- 12.Are there clinical trials I could join, for example of Sirolimus protein-bound particles, Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1), AMPECT?
- 13.Would a second opinion at a high-volume centre change anything, and can you help arrange it?
- 14.What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
- 15.I read that “Malignancy cannot always be predicted from histology”. How does that affect my plan?
- 16.I read that “Resistance to mTOR inhibition eventually develops”. How does that affect my plan?
Tests and results to bring
Biomarker results to ask for: TSC1 or TSC2 inactivation (mTOR inhibitor response), TFE3 fusion (excludes TSC pathway; poor mTOR response), HMB-45, Melan-A and smooth muscle actin co-expression, Size over 5 cm, mitoses, necrosis and infiltration (malignancy criteria).
Scans and tests linked to this cancer: Active surveillance.
Bring copies of scan reports, pathology and blood results, and a list of every medicine and supplement.
The treatments I may be offered
- Localised: Complete resection; surveillance for tumours with malignant features; no proven adjuvant therapy. (Limb-salvage surgery and endoprosthetic reconstruction, Active surveillance)
- Advanced malignant PEComa: Nab-sirolimus (AMPECT; FDA approved 2021); oral sirolimus, everolimus or temsirolimus as alternatives; check TSC status. (Sirolimus protein-bound particles, AMPECT, Everolimus, Temsirolimus, mTOR)
- After mTOR inhibitor: Anthracycline- or gemcitabine-based chemotherapy has modest activity; trials of mTOR-based combinations; PRECISION 1 for TSC-altered tumours. (Doxorubicin, Gemcitabine, Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1))
From the standard of care recorded for this cancer; which apply depends on your stage and biomarkers. Ask which the team recommends and why.